Study	Reason for exclusion
Corr 2015	Cohort study using historical control patients.
Downs 2012	Phase 2 open‐label, non‐randomized (single‐group assignment) trial using fondaparinux days 1‐28 with duplex ultrasonography of the lower extremities between days 28‐35. Results are not published. Recruitment was completed January 2009 (n = 44), of which 17 patients did not complete the study. Of the 27 remaining patients, 0 patients were diagnosed with a VTE at week 4, although 1 patient of the 33 patients who received at least one dose of fondaparinux (and could be assessed for adverse events) experienced a pulmonary embolism and 1 developed a retroperitoneal hematoma.
GlaxoSmithKline 2009	Phase 3 trial enrollment reported as complete (n = 127) February 2007. No results reported. No duration of LMWH or objective VTE measurement defined in protocol.
Huh, 2017	Terminated due to poor enrollment (total patients, n = 7; 4 in control arm, 3 in experimental). No statistical analysis performed.
Krasinski 2014	Prospective, non‐randomized trial.
Rasmussen 2003	Double publication. Data included in the Rasmussen 2006 trial.
Rasmussen 2003a	Publication is a review and not a primary trial.
Sakon 2012	Extended prophylaxis using an oral direct factor Xa inhibitor (Darexaban, YM150).
Schmeler 2013	Cohort study using historical control patients.

LMWH: low molecular weight heparin; VTE: venous thromboembolism.